News & Updates
Filter by Specialty:
Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer
The investigational KRAS G12C inhibitor sotorasib appears to be active against previously treated KRAS p.G12C–mutated advanced pancreatic cancer while having an acceptable safety profile, according to the results of a phase I/II trial.
Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer
11 Feb 2023
Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?
Patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) exhibited significantly improved progression-free survival (PFS) when treated with lazertinib compared with gefitinib in the first-line setting, results of the LASER301 trial showed.
Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?
10 Feb 2023
Alcohol drinking blamed for rise in colorectal cancer cases among young adults
Consumption of alcohol appears to be a risk factor for early-onset colorectal cancer and has driven an increase in the incidence of colorectal cancer among young adults, as shown in a study.
Alcohol drinking blamed for rise in colorectal cancer cases among young adults
10 Feb 2023
Mutational ctDNA analysis helps predict benefit of 2L ripretinib or sunitinib in GIST
Next-generation sequencing (NGS)–based analysis of circulating tumour DNA (ctDNA) helps predict benefit of second-line (2L) ripretinib or sunitinib therapy in patients with imatinib-resistant advanced gastrointestinal stromal tumours (GIST), an exploratory subanalysis of the INTRIGUE trial has shown.
Mutational ctDNA analysis helps predict benefit of 2L ripretinib or sunitinib in GIST
07 Feb 2023
Radiation therapy may raise colorectal cancer risk among Hodgkin's lymphoma survivors
Individuals who received radiation therapy for Hodgkin's lymphoma are at increased risk of colorectal cancer, as reported in a study.
Radiation therapy may raise colorectal cancer risk among Hodgkin's lymphoma survivors
06 Feb 2023
SPOTLIGHT shines on zolbetuximab-chemo potential for gastric/GEJ cancer
A combination regimen comprising zolbetuximab and mFOLFOX6* chemotherapy (CT) regimen showed potential as first-line treatment for claudin-18.2-positive**/HER2-negative (CLDN18.2+/HER2–) locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the primary findings of the phase III SPOTLIGHT trial.